Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • The Status of Pharma...

    The Status of Pharma Sector Reviewed in Parliament

    Written by Geeta Sharma Sharma Published On 2016-03-09T18:00:39+05:30  |  Updated On 9 March 2016 6:00 PM IST
    The Status of Pharma Sector Reviewed in Parliament
    New Delhi: The Rajya Sabha has taken cognisance of risks prevailing due to the exiting drug irregularities, on the consumer market of the country. Discussing in detail sale of spurious drugs, online sale of medicines and an assessment of the impact arising out of custom duty hike, Health Minister Mr. JP Nadda informed members of parliament with the line of action taken so far by his ministry to maintain checks and balances on suspected and confirmed irregularities prevailing in the pharma industry.

    Spurious Drug Racket


    Talking about the spurious drug racket, the Minister Health informed the parliament that over 47,000 drug samples had been picked up in a nation-wide survey in 2015, by the Ministry of Health and Family Welfare to determine the extent of Spurious/Not of Standard Quality drugs in the country. He however accepted that the results had yet to be compiled for the same.

    Talking about the measures taken so far to ensure quality maintenance of drugs the Minister spoke about stringent penalties & offences being made cognizable as well as non-bailable;establishing of special designate Courts for trial of offences under the Drugs and Cosmetics Act for speedy disposal of cases; announcement of a ‘Whistle Blower Scheme’ to encourage vigilant public participation; issuance of guidelines to the State Drugs Controllers for taking action on samples of drugs declared spurious or not of standard quality; and instructions to the concerned staff to keep a vigil and draw samples of drugs for test and analysis for monitoring the quality of drugs.

    Talking about action taken against offenders selling spurious drugs in the past Mr. Nadda said action / prosecution was launched as per the provisions of the Drugs and Cosmetics Act, 1940. To further substantiate the Minister informed that based on samples drawn, tested / analysed by drug regulatory officials of the Centre / State, the extent of adulterated/spurious drugs was 0.27, 0.11, 0.16 and 0.11 percent for 2011-12, 2012-13, 2013-14 and 2014-15 respectively.

    Online Sale of Drugs


    Coming to the point of online sale of drugs in the country The Minister said all sale of drugs was regulated by State Licensing Authorities. As per the Drugs and Cosmetics Rules, 1945, drugs specified in Schedule H, H1 or Schedule X cannot be sold except on and in accordance with the prescription of a Registered Medical Practitioner. He emphasised that all prescription drugs could only be sold under the personal supervision of a registered pharmacist from a licensed premises.

    He further stated that besides appointing a sub committee to examine the issue of sale of drugs on internet,the Drug Controller General (India) had in a a letter dated 30.12.2015 has alerted all State/UT Drug Controllers to put a strict vigil on the on-line sale of medicine and take action against those violating the Drugs and Cosmetics Act and Rules.

    Custom Duty Hike


    Discussing the impact on Impact on Healthcare of Customs Duty Hikes, Health Minister, Mr. J.P. Nadda announced that prices of drugs which came under the National List of essential Medicines (NLEM) were linked to the increase/decrease in the Wholesale Price Index (WPI) in terms of Drugs Price Control Order, 2013. Drugs on which custom duty exemption was granted were those that were included in the NLEM, 2015 the Minister Health added.

    Minister Health also made clear that in the likelihood of a declining WPI this year, the price of drugs were also likely to fall. According to Mr. Nadda in respect of non-scheduled drugs, the annual increase in the Maximum Retail Price (MRP) could not be raised beyond 10%.









    *****
    custom dutyonline sale of drugs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Geeta Sharma Sharma
    Geeta Sharma Sharma
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok